1. Introduction and Background
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the adrenocorticotropic hormone fragment ACTH(4-10), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the late 1980s. The peptide was designed through systematic structural modification of the endogenous ACTH(4-10) sequence, with the addition of a C-terminal Pro-Gly-Pro tripeptide motif that substantially enhances metabolic stability against aminopeptidase and carboxypeptidase degradation (Kaplan et al., 1996). This modification extends the biological half-life of the molecule from minutes to several hours whilst preserving and amplifying the nootropic properties inherent to the parent melanocortin fragment.
The ACTH(4-10) fragment itself had been identified in earlier neurochemical research as the minimal sequence within the full 39-amino-acid adrenocorticotropic hormone responsible for behavioural and cognitive effects, operating independently of adrenocortical steroidogenic activity. Unlike the full ACTH molecule, the (4-10) fragment and its analogues do not stimulate corticosteroid release, thereby dissociating the nootropic pharmacology from endocrine perturbation (Kaplan et al., 1996). Semax has been studied extensively in preclinical models of neurodegeneration, cerebrovascular injury, and cognitive impairment, as well as in a limited number of clinical investigations in the Russian Federation where it holds regulatory approval as an intranasal formulation. The present review examines the current evidence base for Semax across these domains, with particular emphasis on its neurotrophic signalling mechanisms and neuroprotective properties.
2. Molecular Pharmacology and Mechanism of Action
2.1 Neurotrophic Factor Expression: BDNF and NGF
A primary area of mechanistic investigation concerns the capacity of Semax to modulate the expression of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Dolotov and colleagues demonstrated that systemic administration of Semax in rats produced significant upregulation of both BDNF mRNA and its high-affinity receptor TrkB within the hippocampus, a region critically involved in learning and memory consolidation (Dolotov et al., 2006). The magnitude of BDNF upregulation was time-dependent, with peak expression observed between 3 and 6 hours post-administration, suggesting a transcriptional mechanism rather than direct protein stabilisation.
Complementary work by Agapova et al. extended these findings by examining the temporal dynamics of both BDNF and NGF gene expression across multiple brain regions following Semax administration. Their results confirmed region-specific upregulation of neurotrophins in the hippocampus and frontal cortex, with distinct temporal profiles for each factor: BDNF expression peaked earlier and returned to baseline more rapidly than NGF, which showed a more sustained elevation over 24 hours (Agapova et al., 2008). These differential kinetics suggest that Semax may engage multiple upstream transcriptional programmes rather than operating through a single signalling cascade.
The functional significance of this neurotrophic modulation is substantial. BDNF signalling through the TrkB receptor activates downstream pathways including PI3K/Akt and MAPK/ERK, which are established mediators of neuronal survival, synaptic plasticity, and long-term potentiation. NGF, acting primarily through TrkA receptors, supports cholinergic neuron viability and function. The capacity of a single peptide to enhance both pathways simultaneously is of considerable interest to neuroscience research, as deficits in BDNF and NGF signalling have been implicated in the pathophysiology of numerous neurodegenerative conditions (Dolotov et al., 2006).
2.2 Monoaminergic Neurotransmitter Systems
Beyond neurotrophic factor modulation, Semax has been shown to influence central monoaminergic neurotransmission. Eremin et al. demonstrated that acute and chronic Semax administration in rodents produced measurable alterations in dopaminergic and serotoninergic activity across several brain regions, including the striatum, nucleus accumbens, and hypothalamus (Eremin et al., 2005). Specifically, the peptide increased levels of dopamine and serotonin metabolites (DOPAC, HVA, and 5-HIAA) in a dose-dependent manner, indicating enhanced monoamine turnover rather than simple reuptake inhibition. These neurochemical effects are consistent with the observed behavioural profile of Semax in attention and motivation paradigms, and provide a mechanistic basis for its classification within the nootropic peptide family. Importantly, the monoaminergic effects appear to be modulatory rather than pharmacologically overwhelming, as Semax does not produce the hyperlocomotion or stereotypic behaviours characteristic of direct dopamine agonists.
3. Neuroprotection Research
3.1 Cerebral Ischaemia Models
The most extensively investigated neuroprotective application of Semax involves models of cerebral ischaemia. Gusev et al. conducted clinical and electrophysiological studies in patients presenting with acute hemispheric ischaemic stroke, reporting that intranasal Semax administration during the acute phase was associated with improved neurological outcomes and accelerated recovery of somatosensory evoked potentials relative to standard care (Gusev et al., 1997). While methodological limitations of this early clinical work warrant acknowledgement, including relatively small sample sizes and the absence of placebo blinding in some cohorts, the findings provided an initial clinical rationale for further mechanistic investigation.
More recent preclinical work has substantially advanced understanding of the transcriptomic response to Semax following cerebral ischaemia. Filippenkov and colleagues employed genome-wide RNA sequencing in a rat model of transient middle cerebral artery occlusion (MCAO) to characterise the molecular landscape influenced by Semax treatment. Their analysis revealed that Semax administration modulated the expression of hundreds of genes involved in inflammation, apoptosis, and vascular remodelling during the reperfusion phase (Filippenkov et al., 2020). Notably, the peptide attenuated the upregulation of pro-inflammatory cytokine genes (including Il-1β and Tnf) whilst preserving the expression of anti-apoptotic factors, suggesting a shift in the post-ischaemic transcriptional programme toward neuroprotective and reparative pathways.
Extending this transcriptomic approach, Dergunova et al. identified a broader set of differentially expressed genes in the MCAO model and demonstrated that many of the ischaemia-induced transcriptional changes were substantially normalised by Semax treatment (Dergunova et al., 2018). Pathway enrichment analysis highlighted particular effects on genes governing immune cell infiltration, blood-brain barrier integrity, and glial activation, providing a systems-level framework for understanding the peptide's neuroprotective capacity that extends well beyond its neurotrophic actions alone.
3.2 Dopaminergic Neurodegeneration
Semax has also been evaluated in models of dopaminergic neurodegeneration relevant to Parkinson's disease pathology. Levitskaya et al. investigated the effects of the peptide in an MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model, which produces selective destruction of nigrostriatal dopaminergic neurons through mitochondrial complex I inhibition. Semax administration attenuated MPTP-induced motor deficits and partially preserved striatal dopamine levels compared to untreated controls (Levitskaya et al., 2004). The protective mechanism was proposed to involve both direct neurotrophic support to vulnerable dopaminergic neurons and modulation of the neuroinflammatory response that accompanies MPTP toxicity. These findings, whilst preliminary, suggest that the neuroprotective envelope of Semax may extend beyond acute ischaemic injury to encompass chronic neurodegenerative processes, though this remains to be confirmed in more comprehensive preclinical programmes.
4. Cognitive and Behavioural Studies
The nootropic properties of Semax have been assessed across a range of behavioural paradigms in rodent models. Studies utilising the Morris water maze, passive avoidance, and novel object recognition tasks have consistently demonstrated that Semax enhances acquisition, consolidation, and retrieval of spatial and associative memory (Kaplan et al., 1996). The magnitude of cognitive enhancement observed in these models correlates temporally with the upregulation of hippocampal BDNF expression documented by Dolotov and colleagues, supporting a mechanistic link between the peptide's neurotrophic actions and its pro-cognitive behavioural profile (Dolotov et al., 2006).
Of particular interest are findings from developmental neurotoxicity paradigms. Glazova et al. examined the capacity of Semax to attenuate behavioural and neurochemical alterations induced by early-life exposure to fluvoxamine, a selective serotonin reuptake inhibitor. Their results demonstrated that Semax treatment normalised anxiety-like behaviour and restored monoaminergic balance in adult rats that had experienced neonatal SSRI exposure (Glazova et al., 2021). These data indicate that the peptide's cognitive and behavioural effects may encompass not only enhancement of normal function but also restoration of function following neurodevelopmental perturbation.
The involvement of both neurotrophic and monoaminergic pathways in Semax's cognitive profile distinguishes it from classical nootropic compounds that typically operate through a single neurotransmitter system. The simultaneous enhancement of BDNF-mediated synaptic plasticity and dopaminergic/serotoninergic neurotransmission may produce synergistic effects on attentional processing, working memory, and learning that would not be achievable through modulation of either system in isolation (Eremin et al., 2005).
5. Current Directions and Future Research
Contemporary research on Semax is advancing along several productive trajectories. The application of high-throughput transcriptomic and proteomic methodologies has begun to reveal the full scope of molecular programmes influenced by the peptide, moving the field beyond candidate gene approaches toward systems-level understanding (Filippenkov et al., 2020) (Dergunova et al., 2018). These omics-based approaches are particularly valuable for identifying novel downstream effectors and potential biomarkers of response that may inform future study design.
A critical gap in the current literature concerns the relative paucity of well-powered, placebo- controlled clinical trials conducted according to contemporary regulatory standards. While the clinical investigations undertaken in the Russian Federation provided encouraging preliminary data, the evidence base would benefit substantially from multi-centre trials incorporating modern outcome measures, neuroimaging endpoints, and extended follow-up periods. The intranasal route of administration employed in existing clinical work represents a practical advantage for potential translation, as it offers rapid central nervous system access via the olfactory and trigeminal nerve pathways whilst avoiding first-pass hepatic metabolism.
Emerging areas of investigation include the potential epigenetic mechanisms underlying Semax's neurotrophic effects, given that the temporal dynamics of BDNF and NGF upregulation are consistent with chromatin remodelling processes (Agapova et al., 2008). Additionally, the development of next-generation analogues with enhanced blood-brain barrier permeability or extended duration of action continues to be an active area of medicinal chemistry research. The convergence of advanced genomic tools with established preclinical models positions Semax research to make meaningful contributions to the broader understanding of melanocortin-derived peptides in neuroscience, although definitive conclusions regarding translational applicability will require substantially more rigorous clinical evidence than is currently available.
6. Conclusions
Semax represents a rationally designed synthetic analogue of the ACTH(4-10) fragment that has demonstrated consistent neurotrophic, neuroprotective, and pro-cognitive properties across a broad range of preclinical experimental paradigms. Its principal mechanisms of action involve the transcriptional upregulation of BDNF and NGF in hippocampal and cortical regions, modulation of dopaminergic and serotoninergic neurotransmission, and attenuation of pro-inflammatory and pro-apoptotic gene expression programmes in models of cerebral ischaemia. The dissociation of these neurotropic effects from the endocrine activity of the parent ACTH molecule represents a significant pharmacological advantage. However, the current evidence base remains predominantly preclinical, and the limited clinical data available do not yet meet the methodological standards required for definitive efficacy conclusions. Future research incorporating rigorous clinical trial design, transcriptomic biomarker strategies, and next-generation analogue development will be essential to fully characterise the therapeutic potential of this peptide class.